Welcome to SARomics Biostructures

Here we present company news & various activities and discuss how we help customers accelerate their lead discovery projects!

WAC™ screening technology: seven years after commercial implementation

Compound library screening in drug discovery aims to identify a compound or a series of compounds that can bind to the drug target and modulate its activity. Here, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.  

Read More

2023 – Another Successful Year

The examples in this post demonstrate some representative projects and company business development activities in 2023. The scientific part shows the applications of the three main areas of our expertise: X-ray crystallography, NMR spectroscopy, and integrated drug discovery.

Read More

Structure-Based Drug Design at Room Temperature

New insights show that room-temperature and multi-temperature crystallography may be used in the study of functionally important conformations. This can be used to reveal temperature-dependent differences in protein-ligand interactions, including unique binding poses and even new binding sites.

Read More

Biosimilars: Why is NMR spectroscopy the best method for comparability assessment?

The third article in our series about therapeutic monoclonal antibodies focuses on structural characterization and comparability analysis of biosimilars. We discuss existing evidence that shows that NMR spectroscopy is far superior to other established methods for comparability assessment, like FTIR, UV and circular dichroism (CD) spectroscopy, and differential scanning calorimetry (DSC).

Read More